Efficacy News and Research

RSS

Researchers identify traditional Ghanaian medicines to eradicate neglected tropical diseases

The discovery of new drugs is vital to achieving the eradication of neglected tropical diseases (NTDs) in Africa and around the world.

4 Jan 2021

Study shows mRNA-1273 vaccine can prevent symptomatic COVID-19 infection

A peer-reviewed paper published in The New England Journal of Medicine provides data from the much-anticipated COVE study, which evaluated mRNA-1273, a vaccine candidate against COVID-19 manufactured by Moderna, Inc.

3 Jan 2021

Phase 3 results show investigational vaccine is effective in preventing severe COVID-19

The investigational vaccine known as mRNA-1273 was 94.1% efficacious in preventing symptomatic coronavirus disease 2019 (COVID-19), according to preliminary results from a Phase 3 clinical trial reported in the New England Journal of Medicine.

3 Jan 2021

WHO lists Comirnaty COVID-19 mRNA vaccine for emergency use

The World Health Organization (WHO) today listed the Comirnaty COVID-19 mRNA vaccine for emergency use, making the Pfizer/BioNTech vaccine the first to receive emergency validation from WHO since the outbreak began a year ago.

3 Jan 2021

Stopping RAS inhibitors linked to risk of adverse outcomes in patients with chronic kidney disease

Small studies have suggested that a group of medications called RAS inhibitors may be harmful in persons with advanced chronic kidney disease, and physicians therefore often stop the treatment in such patients.

29 Dec 2020

Scientists identify distinct sub-types of angiosarcomas to allow for targeted treatment

A new study led by clinician-scientists from the National Cancer Centre Singapore, with collaborators from research institutions worldwide, has found that angiosarcomas have unique genomic and immune profiles which allow them to be classified into three different subtypes.

28 Dec 2020

Phase 3 trial of Novavax COVID-19 vaccine candidate begins enrolling volunteers

The Phase 3 trial of another investigational coronavirus disease 2019 (COVID-19) vaccine has begun enrolling adult volunteers.

28 Dec 2020

Could engineered red blood cells be an effective antiviral against SARS-CoV-2?

In a new study, released on the bioRxiv* preprint server, a team of researchers explores the antiviral potential of red blood cells against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of COVID-19.

24 Dec 2020

Kobe University and Sysmex conduct joint research on ELISPOT method for identifying COVID-19

Kobe University and Sysmex Corporation have been engaged in joint research on the ELISPOT method, a new blood test for identifying the novel coronavirus disease (COVID-19).

24 Dec 2020

Nasolaryngoscopy hood effectively reduces aerosol exposures to patients

The COVID-19 pandemic has continued to cause dramatic shifts in the practice of otolaryngology. Even with standard precautions such as physical distancing and wearing personal protective equipment, aerosol-generating procedures such as nasolaryngoscopy (a commonly performed in-office procedure in which a soft, flexible fiber-scope is passed through the nose and into the throat) and intranasal instrumentation were determined to carry a risk of potential transmission if not adequately protected.

23 Dec 2020

At risk of extinction, black-footed ferrets get experimental COVID vaccine

In late summer, as researchers accelerated the first clinical trials of COVID-19 vaccines for humans, a group of scientists in Colorado worked to inoculate a far more fragile species.

23 Dec 2020

Cell-mediated immunity may be more important than neutralizing antibodies in COVID-19 outcome

A new study sheds light on some important differences between asymptomatic and symptomatic patients with coronavirus disease 2019 (COVID-19).

23 Dec 2020

Researchers use fruit fly model to understand COVID-19-related neurological complications

Researchers claim to have reproduced disease mechanisms due to coronavirus disease 2019 (COVID-19) in the fruit fly, Drosophila, while also providing proof of the efficacy of one drug against these disease processes. If validated, these findings represent a new understanding of how the virus causes neurological symptoms that could help develop more effective therapies.

23 Dec 2020

Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals

Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021. Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe COVID-19 expected in the coming days; this non-powered study was designed to evaluate safety and potential identification of preliminary efficacy signals in support of the global Phase 2/3 study of opaganib.

23 Dec 2020

Early clinical data demonstrates the efficacy of existing drug in treating COVID-19

In what has the potential to significantly change how Corona patients are being treated and the severity of the disease, research spearheaded at Jerusalem's Hebrew University gathered early clinical evidence demonstrating the efficacy of an existing drug in treating COVID-19.

22 Dec 2020

COVID-19 patients retain immunity against the virus for at least 8 months

Australian researchers have revealed - for the first time - that people who have been infected with the COVID-19 virus have immune memory to protect against reinfection for at least eight months.

22 Dec 2020

A hand-held device that measures aerosols could help prevent spread of COVID-19

Hand-held devices may be vital in the fight against the COVID-19 pandemic, given the important role that aerosols play in the transmission of the virus.

22 Dec 2020

Immune-inflammatory mediators indicate that rejection and tissue injury can be avoided with drugs

Immune inflammatory mediators are critical in pathology, transplantation, and regenerative medicine, scientists report in The American Journal of Pathology

22 Dec 2020

Nocturnal respiratory rate of heart patients can help predict the success of ICD treatment

onditions causing arrhythmia are among the most common cardiac conditions. A study headed by Prof. Georg Schmidt of the Technical University of Munich has demonstrated for the first time that the nocturnal respiratory rate can help with an important prediction: It is an indicator of whether a defibrillator will help to extend the life of patients with arrhythmia.

21 Dec 2020

First patient enrolled in Phase II clinical trial of stem cell therapy for traumatic injuries

The first patient has enrolled in a Phase II clinical trial evaluating a stem cell therapy for the potential early treatment of traumatic injuries and their subsequent complications at The University of Texas Health Science Center at Houston.

21 Dec 2020

Efficacy News and Research

Researchers identify traditional Ghanaian medicines to eradicate neglected tropical diseases

Study shows mRNA-1273 vaccine can prevent symptomatic COVID-19 infection

Phase 3 results show investigational vaccine is effective in preventing severe COVID-19

WHO lists Comirnaty COVID-19 mRNA vaccine for emergency use

Stopping RAS inhibitors linked to risk of adverse outcomes in patients with chronic kidney disease

Scientists identify distinct sub-types of angiosarcomas to allow for targeted treatment

Phase 3 trial of Novavax COVID-19 vaccine candidate begins enrolling volunteers

Could engineered red blood cells be an effective antiviral against SARS-CoV-2?

Kobe University and Sysmex conduct joint research on ELISPOT method for identifying COVID-19

Nasolaryngoscopy hood effectively reduces aerosol exposures to patients

At risk of extinction, black-footed ferrets get experimental COVID vaccine

Cell-mediated immunity may be more important than neutralizing antibodies in COVID-19 outcome

Researchers use fruit fly model to understand COVID-19-related neurological complications

Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals

Early clinical data demonstrates the efficacy of existing drug in treating COVID-19

COVID-19 patients retain immunity against the virus for at least 8 months

A hand-held device that measures aerosols could help prevent spread of COVID-19

Immune-inflammatory mediators indicate that rejection and tissue injury can be avoided with drugs

Nocturnal respiratory rate of heart patients can help predict the success of ICD treatment

First patient enrolled in Phase II clinical trial of stem cell therapy for traumatic injuries

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News